Legend Biotech is a premier standalone cell therapy pioneer transitioning rapidly from a clinical-stage R&D firm to a highly profitable commercial powerhouse. The investment thesis is anchored by the explosive commercial trajectory of CARVYKTI, its best-in-class BCMA CAR-T therapy co-developed with Johnson & Johnson, which is rapidly penetrating lucrative earlier lines of treatment (2nd and 3rd line). This commercial engine is supported by world-class manufacturing metrics (99% success rate, 29-day median turnaround) that mitigate the historical execution bottlenecks of autologous cell therapies. Furthermore, Legend's proprietary TaVec platform has established clinical proof-of-concept for LB2501, a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T, which could revolutionize the industry by eliminating complex ex vivo manufacturing and lymphodepletion entirely. Backed by a robust cash runway extended by a June 2026 public offering, Legend is on track to achieve company-wide profitability in the second half of 2026.